Flagship Harbor Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Flagship Harbor Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-124	Closed	-$3.31K	–	740
2025 Q4	$3.31K	Buy	+124	New	+$2.96K	﹤0.01%	1744
2020 Q4	–	Sell	-1,148	Closed	-$47K	–	569
2020 Q3	$47K	Buy	1,148 +14	+1%	+$605	0.01%	871
2020 Q2	$54K	Hold	1,134	–	–	0.01%	831
2020 Q1	$48K	Hold	1,134	–	–	0.01%	760
2019 Q4	$49K	Hold	1,134	–	–	0.01%	810
2019 Q3	$40K	Hold	1,134	–	–	0.01%	839
2019 Q2	$30K	Sell	1,134 -7,000	-86%	-$179K	0.01%	917
2019 Q1	$218K	Hold	8,134	–	–	0.04%	380
2018 Q4	$131K	Sell	8,134 -3,000	-27%	-$58.3K	0.03%	460
2018 Q3	$231K	Sell	11,134 -650	-6%	-$10.2K	0.04%	378
2018 Q2	$179K	Buy	+11,784	New	+$210K	0.04%	426
2017 Q4	–	Sell	-6,884	Closed	-$260K	–	371
2017 Q3	$260K	Buy	+6,884	New	+$224K	0.08%	265
2017 Q2	–	Sell	-6,234	Closed	-$202K	–	344
2017 Q1	$202K	Buy	+6,234	New	+$220K	0.08%	300

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Flagship Harbor Advisors's ACAD Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 124 shares — an estimated $3.31K sold.

Flagship Harbor Advisors first reported a position in ACAD in Q1 2017 and held it in 13 quarters. The position peaked at $260K in Q3 2017. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Flagship Harbor Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Flagship Harbor Advisors sold 124 Acadia Pharmaceuticals shares in Q1 2026, an estimated $3.31K.
Flagship Harbor Advisors first reported a position in Acadia Pharmaceuticals in Q1 2017 and held it in 13 quarters.
Flagship Harbor Advisors's Acadia Pharmaceuticals position peaked at $260K in Q3 2017.
343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.